Those following the financial markets and the valuation of biotechnology co
mpanies recently might find themselves perplexed. Towards the end of 1999,
during which the availability of capital for biotech initial public offerin
gs and for private investment rounds seemingly withered, the markets sudden
ly turned around and gave the biotechnology industry its biggest bonanza ev
er.